PMID- 28844870 OWN - NLM STAT- MEDLINE DCOM- 20180521 LR - 20180521 IS - 1873-5169 (Electronic) IS - 0196-9781 (Linking) VI - 96 DP - 2017 Oct TI - Phoenixin-14 injected intracerebroventricularly but not intraperitoneally stimulates food intake in rats. PG - 53-60 LID - S0196-9781(17)30254-1 [pii] LID - 10.1016/j.peptides.2017.08.004 [doi] AB - Phoenixin, a recently discovered 20-amino acid peptide was implicated in reproduction. However, the expression in food intake-regulatory nuclei such as the paraventricular nucleus, the arcuate nucleus and the nucleus of the solitary tract suggests an implication of phoenixin in food intake regulation. Therefore, we investigated the effects of phoenixin-14, the shorter form of phoenixin, on food intake following intracerebroventricular (icv) and intraperitoneal (ip) injection in ad libitum fed male Sprague-Dawley rats. Phoenixin-14 injected icv (0.2, 1.7 or 15nmol/rat) during the light phase induced a dose-dependent increase of light phase food intake reaching significance at a minimum dose of 1.7 nmol/rat (+72%, p<0.05 vs. vehicle) used for all further analyses. Assessment of the food intake microstructure showed an icv phoenixin-14-induced increase in meal size (+51%), meal duration (+157%), time spent in meals (+182%) and eating rate (+123%), while inter-meal intervals (-42%) and the satiety ratio (-64%) were decreased compared to vehicle (p<0.05). When injected icv during the dark phase, no modulation of food intake was observed (p>0.05). The light phase icv phoenixin-14-induced increase of water intake did not reach statistical significance compared to vehicle (+136%, p>0.05). The increase of food intake following icv phoenixin-14 was not associated with a significant alteration of grooming behavior (0.4-fold, p=0.377) or locomotion (6-fold, p=0.066) compared to vehicle. When injected ip at higher doses (0.6, 5nmol/kg or 45nmol/kg body weight) during the light phase, phoenixin-14 did not affect food intake (p>0.05). In summary, phoenixin-14 exerts a centrally-mediated orexigenic effect. CI - Copyright (c) 2017 Elsevier Inc. All rights reserved. FAU - Schalla, Martha AU - Schalla M AD - Charite Center for Internal Medicine and Dermatology, Department for Psychosomatic Medicine; Charite-Universitatsmedizin Berlin, corporate member of Freie Universitat Berlin, Humboldt-Universitat zu Berlin, and Berlin Institute of Health, Berlin, Germany. FAU - Prinz, Philip AU - Prinz P AD - Charite Center for Internal Medicine and Dermatology, Department for Psychosomatic Medicine; Charite-Universitatsmedizin Berlin, corporate member of Freie Universitat Berlin, Humboldt-Universitat zu Berlin, and Berlin Institute of Health, Berlin, Germany. FAU - Friedrich, Tiemo AU - Friedrich T AD - Charite Center for Internal Medicine and Dermatology, Department for Psychosomatic Medicine; Charite-Universitatsmedizin Berlin, corporate member of Freie Universitat Berlin, Humboldt-Universitat zu Berlin, and Berlin Institute of Health, Berlin, Germany. FAU - Scharner, Sophie AU - Scharner S AD - Charite Center for Internal Medicine and Dermatology, Department for Psychosomatic Medicine; Charite-Universitatsmedizin Berlin, corporate member of Freie Universitat Berlin, Humboldt-Universitat zu Berlin, and Berlin Institute of Health, Berlin, Germany. FAU - Kobelt, Peter AU - Kobelt P AD - Charite Center for Internal Medicine and Dermatology, Department for Psychosomatic Medicine; Charite-Universitatsmedizin Berlin, corporate member of Freie Universitat Berlin, Humboldt-Universitat zu Berlin, and Berlin Institute of Health, Berlin, Germany. FAU - Goebel-Stengel, Miriam AU - Goebel-Stengel M AD - Charite Center for Internal Medicine and Dermatology, Department for Psychosomatic Medicine; Charite-Universitatsmedizin Berlin, corporate member of Freie Universitat Berlin, Humboldt-Universitat zu Berlin, and Berlin Institute of Health, Berlin, Germany; Department of Internal Medicine, Helios Clinic, Zerbst, Germany. FAU - Rose, Matthias AU - Rose M AD - Charite Center for Internal Medicine and Dermatology, Department for Psychosomatic Medicine; Charite-Universitatsmedizin Berlin, corporate member of Freie Universitat Berlin, Humboldt-Universitat zu Berlin, and Berlin Institute of Health, Berlin, Germany; Department of Quantitative Health Sciences, Medical School University of Massachusetts, Worcester, MA, USA. FAU - Stengel, Andreas AU - Stengel A AD - Charite Center for Internal Medicine and Dermatology, Department for Psychosomatic Medicine; Charite-Universitatsmedizin Berlin, corporate member of Freie Universitat Berlin, Humboldt-Universitat zu Berlin, and Berlin Institute of Health, Berlin, Germany; Department of Psychosomatic Medicine and Psychotherapy, Medical University Hospital Tubingen, Tubingen, Germany. Electronic address: andreas.stengel@charite.de. LA - eng PT - Journal Article DEP - 20170824 PL - United States TA - Peptides JT - Peptides JID - 8008690 RN - 0 (Central Nervous System Stimulants) RN - 0 (Peptides) SB - IM MH - Animals MH - Central Nervous System Stimulants MH - Eating/*drug effects MH - Feeding Behavior/*drug effects MH - Injections, Intraperitoneal MH - Injections, Intraventricular MH - Male MH - Peptides/*administration & dosage/*pharmacology MH - Rats MH - Rats, Sprague-Dawley OTO - NOTNLM OT - Behavior OT - Brain-gut-axis OT - Food intake microstructure OT - Orexigenic OT - Water intake EDAT- 2017/08/29 06:00 MHDA- 2018/05/22 06:00 CRDT- 2017/08/29 06:00 PHST- 2017/05/12 00:00 [received] PHST- 2017/08/10 00:00 [revised] PHST- 2017/08/14 00:00 [accepted] PHST- 2017/08/29 06:00 [pubmed] PHST- 2018/05/22 06:00 [medline] PHST- 2017/08/29 06:00 [entrez] AID - S0196-9781(17)30254-1 [pii] AID - 10.1016/j.peptides.2017.08.004 [doi] PST - ppublish SO - Peptides. 2017 Oct;96:53-60. doi: 10.1016/j.peptides.2017.08.004. Epub 2017 Aug 24.